CD38 and Miyoshi myopathy: Huang et al. used a new type of NPs to pack the STAT3 inhibitors, and modified these NPs with monoclonal anti-CD38 antibodies to further enhance the therapeutic efficacy of STAT3 inhibitors on MM.